Cargando…

A66 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY

BACKGROUND: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are acid suppressant drugs indicated in highly prevalent conditions such as gastroesophageal reflux disease and peptic ulcer disease. A recent observational study reported an increased risk of inflammatory bowel d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanofsky, R P, Abrahami, D, Pradhan, R, Yin, H, McDonald, E G, Bitton, A, Azoulay, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991348/ http://dx.doi.org/10.1093/jcag/gwac036.066

Ejemplares similares

Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer’
por: Abrahami, Devin, et al.
Publicado: (2022)

A197 INVESTIGATING THE PROTON-PUMP INHIBITOR USE PRECEDING AND POST AN INFLAMMATORY BOWEL DISEASE DIAGNOSIS
por: Singh, N, et al.
Publicado: (2023)

A80 DEVELOPMENT OF COMPETENCY BASED MEDICAL EDUCATION CURRICULUM FOR INFLAMMATORY BOWEL DISEASE ADVANCED TRAINING PROGRAM IN CANADA
por: Yanofsky, R P, et al.
Publicado: (2023)

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
por: Abrahami, Devin, et al.
Publicado: (2018)

Proton pump inhibitors and the incidence of Clostridium difficile on the intensive care unit
por: Whitehead, I, et al.
Publicado: (2007)

A146 BENIGN GASTRIC ULCER COMPLICATED BY GASTROJEJUNAL FISTULA FORMATION HEALED WITH PROTON-PUMP INHIBITOR
por: Winter, R, et al.
Publicado: (2023)

A149 CHARACTERIZING INAPPROPRIATE PROTON-PUMP INHIBITOR DISCONTINUATION IN PATIENTS WITH ESOPHAGEAL STRICTURES
por: Kecskemeti, K L, et al.
Publicado: (2023)

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES
por: Bedi, H, et al.
Publicado: (2023)

A169 THE DIRECT COSTS OF INFLAMMATORY BOWEL DISEASE IN CANADA: A POPULATION-BASED ANALYSIS OF HISTORICAL AND CURRENT COSTS
por: Coward, S, et al.
Publicado: (2023)

A183 VARIATION IN HEALTH SERVICES UTILIZATION AND RISK OF SURGERY ACROSS CHILDREN WITH INFLAMMATORY BOWEL DISEASE: A MULTIPROVINCE COHORT STUDY
por: Kuenzig, E, et al.
Publicado: (2023)

A68 HOW REAL ARE YOUR SURVEY RESPONDENTS? IDENTIFYING FRAUDULENT RESPONDENTS IN ONLINE SURVEYS – A CASE EXAMPLE IN INFLAMMATORY BOWEL DISEASE (IBD)
por: MacDonald, K V, et al.
Publicado: (2023)

PA01.66. Importance of upayogasamstha in relation to digestion of the food
por: Avhad, Anil D., et al.
Publicado: (2012)

Inflammatory arthritis associated with inflammatory bowel disease in children
por: Desgranges, M, et al.
Publicado: (2008)

Effect of proton pump inhibitors on gastric volume, gastric pH and gastric intramucosal pH in critically ill patients in the ICU
por: Gursoy, O, et al.
Publicado: (2006)

Genetic polymorphisms of inflammatory molecules in Tunisian inflammatory bowel diseases
por: Gorgi, Y, et al.
Publicado: (2010)

A220 ONTARIO POPULATION TRENDS IN INTESTINAL AND EXTRA-INTESTINAL CANCERS OVER 25 YEARS AMONG PERSONS WITH INFLAMMATORY BOWEL DISEASES AND MATCHED CONTROLS
por: Murthy, S K, et al.
Publicado: (2023)

Effects of proton pump inhibitor versus H2-receptor antagonist stress ulcer prophylaxis on ventilator-associated pneumonia: a pilot study
por: Fogas, JF, et al.
Publicado: (2013)

Prostate cancer: histopathological analysis of 66 cases
por: Oluwole, Olabode Peter, et al.
Publicado: (2011)

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011
por: Kanerva, M, et al.
Publicado: (2013)

Influence of proton pump inhibitor use on clinical outcomes of patients with inflammatory bowel disease
por: Choden, Tenzin, et al.
Publicado: (2023)

Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study
por: Abrahami, Devin, et al.
Publicado: (2020)

A189 EMERGENCY DEPARTMENT UTILIZATION AND RISK OF INTESTINAL RESECTION IS LOWER AMONG CHILDREN DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BEFORE 10 YEARS OF AGE: A MULTIPROVINCE POPULATION-BASED COHORT STUDY
por: Kuenzig, E, et al.
Publicado: (2023)

P02.66. Efficacy of acupuncture for fibromyalgia - RCT
por: Vinjamury, S, et al.
Publicado: (2012)

A66 THE IMPACT OF A MULTIDISCIPLINARY ADOLESCENT AND YOUNG ADULT (AYA) INFLAMMATORY BOWEL DISEASE (IBD) ON CLINIC NO SHOW RATES
por: Sharma, R, et al.
Publicado: (2022)

A214 WOMEN WITH INFLAMMATORY BOWEL DISEASE HAVE INCREASED HEALTH-CARE UTILIZATION DURING PREGNANCY AND POSTPARTUM COMPARED TO THOSE WITHOUT INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED COHORT STUDY
por: Tandon, P, et al.
Publicado: (2023)

Clinical and genetic analyses in a patient with PAPA syndrome complicated with inflammatory bowel disease
por: Ida, H, et al.
Publicado: (2015)

On-pump versus off-pump coronary artery bypass grafting: relationship between complications and released cytokines after on-pump surgery
por: Nigri, M, et al.
Publicado: (2005)

A225 QUANTIFICATION OF BONE DENSITY AND DIETARY RISK FACTORS FOR BONE FRAGILITY IN INFLAMMATORY BOWEL DISEASE
por: Macci, A, et al.
Publicado: (2023)

P008 A systematic review and meta-analysis of inflammatory bowel disease activity and sleep quality
por: Barnes, A, et al.
Publicado: (2021)

Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
por: Rothrock, JF, et al.
Publicado: (2013)

Ward outings: providing patients with meal support in the real world
por: Litchfield, Heather
Publicado: (2015)

Colorectal cancer risk in patients with inflammatory bowel disease and Lynch syndrome
por: Aronson, Melyssa, et al.
Publicado: (2010)

A202 INVESTIGATION OF THE DIRECT EFFECT OF HEMIN-HEMOPEXIN AND HAPTOGLOBIN STIMULATION IN INFLAMMATORY BOWEL DISEASE
por: Ajayi, A S, et al.
Publicado: (2023)

P02.120. Qualitative systemic review on Complementary and Alternative Medicine treatments in Inflammatory Bowel Diseases
por: Langhorst, J, et al.
Publicado: (2012)

A159 RISK OF TOTAL METACHRONOUS ADVANCED NEOPLASIA IN PATIENTS WITH SERRATED LESIONS AND INFLAMMATORY BOWEL DISEASE
por: Medawar, E, et al.
Publicado: (2023)

A nonrandomized comparison of off -pump versus on-pump coronary bypass surgery in Egyptian patients
por: El-Abd, H, et al.
Publicado: (2011)

Proton pump inhibitors use and risk of inflammatory bowel diseases: a meta-analysis of observational studies
por: Shastri, Sanjana Aditya, et al.
Publicado: (2022)

New real-time bowel sound analysis may predict disease severity in septic patients
por: Goto, J, et al.
Publicado: (2015)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_njljjd182cj690ng7fhn41silo